OrganiGram Announces Brokered Private Placement
MONCTON, NEW BRUNSWICK–(Marketwired – Dec 5, 2014) – OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OGRMF) (the “Company“) is pleased to announce that it has engaged Jacob Securities Inc. (the “Agent”) in connection with a proposed private placement (the “Offering), on a best efforts basis, whereby the Company intends to raise aggregate gross proceeds of a minimum of $4,000,000 and up to $6,000,000 at a price of $0.85 per unit. There is also an over-allotment option exercisable by the Agent prior to and for a period of 30 days following the Closing Date to raise additional gross proceeds of up to 15% of the maximum Offering.
Each unit will be comprised of one common share and one common share purchase warrant (the “Warrants”). Each Warrant will entitle the holder to purchase one additional common share of the Corporation at a price of $1.00 per share for a period of 36 months from the date of issue.
The Company will pay the Agent a commission of 6% cash (3% for Units issued through a Presidents List) on gross proceeds raised through the sale of the Units and issue broker warrants to acquire 6% (3% for Presidents List) of the total number of units issued, under this Offering. Each broker warrant will entitle the holder to subscribe for one common share of the Corporation at a price of $1.00 for a period of 24 months from the date of issue.
Proceeds from this Offering will be used by the Company to expedite the expansion of its medical marijuana facility in order to keep pace with the increase in demand for its products.
The anticipated closing of the Offering is December 12, 2014 (or such other date as may be agreed upon by the Company and the Agent).
Completion of this placement is subject to the approval of the TSX Venture Exchange.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.
Please visit www.organigram.ca for more information.
On Behalf of the Board of Directors of Organigram,
Denis Arsenault, Director & CEO
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Director of Investor Relations
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | firstname.lastname@example.org